Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community GT20029. Kintor Pharma’s Product

      in Research/Science  12 upvotes 3 years ago
      The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

      community topical fluridil/eucapil + dut to block all DHT+T from scalp?

      in Treatment  8 upvotes 4 years ago
      User experienced slow gains with topical fin+min, switched to topical dut+min, and considered adding Eucapil. Another user suggested DUT may be less effective topically due to high molar mass and mentioned Fluridil as a weak anti-androgen that could help.

      community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound

      in Research/Science  128 upvotes 3 years ago
      The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

      community Any long term RU55841 / CB-03-01 / Eucapil users here?

      in Research/Science  9 upvotes 5 years ago
      Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

      community Anagenic is trying to compound Gt20029

      in Treatment  56 upvotes 3 years ago
      The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.